Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Novartis (Details)

v3.20.1
Licensing and Other Arrangements - Novartis (Details)
$ / shares in Units, $ in Thousands, € in Millions
 12 Months Ended
Aug. 24, 2017
EUR (€)
agreement
item
shares
Aug. 24, 2017
USD ($)
agreement
item
$ / shares
shares
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2018
USD ($)
shares
Dec. 31, 2017
USD ($)
Licensing and other arrangements          
Proceeds from issuance of common stock     $ 21,929 $ 6,063  
Issuance of common stock, fair value     21,762 5,866  
Revenue from contracts with customers     $ 17,276 $ 5,068  
Common Stock          
Licensing and other arrangements          
Issuance of common stock, net (in shares) | shares     1,000,000 354,000  
Issuance of common stock, fair value     $ 8 $ 2  
XOMA-052 License Agreement | Common Stock          
Licensing and other arrangements          
Closing stock price (in dollars per share) | $ / shares   $ 8.93      
Novartis Pharma AG          
Licensing and other arrangements          
Common stock premium   $ 200      
Novartis Pharma AG | XOMA052 License Agreement and I L1 Target License Agreement          
Licensing and other arrangements          
Upfront payment received   25,700      
License agreement consideration received, repayment of debt   $ 14,300      
Number of license agreements | agreement 2 2      
Number of arrangements | item 1 1      
Remaining performance obligations   $ 0      
Number of performance obligations | item 2 2      
Transaction price   $ 40,200      
Revenue from contracts with customers     0 0 $ 40,200
Contract assets     0 0  
Contract liabilities     0 0  
Capitalized contract costs     $ 0 $ 0  
Novartis Pharma AG | XOMA-052 License Agreement          
Licensing and other arrangements          
License agreement consideration received   30,000      
Upfront payment received   15,700      
License agreement consideration received, repayment of debt € 12.0 14,300      
Proceeds from issuance of common stock   5,000      
Common stock premium   200      
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   $ 438,000      
Agreement termination prior written notice period 6 months 6 months      
Novartis Pharma AG | XOMA-052 License Agreement | Common Stock          
Licensing and other arrangements          
Issuance of common stock, net (in shares) | shares 539,131 539,131      
Purchase price (in dollars per share) | $ / shares   $ 9.2742      
Issuance of common stock, fair value   $ 4,800      
Novartis Pharma AG | IL-1 Target License Agreement          
Licensing and other arrangements          
Upfront payment received   $ 10,000